Oncologist-approved cancer information from the American Society of Clinical Oncology

Leukemia

News and highlights from ASCO Annual Meetings.


Category :
Year :
 
 
New Drug Effective as First Treatment for Chronic Myeloid Leukemia
June 2, 2007

Dasatinib (Sprycel) is effective as an initial treatment for newly diagnosed patients with chronic phase (early stage) chronic myeloid leukemia (CML), according to a phase II clinical trial from The University of Texas M. D. Anderson Cancer Center in Houston.
Arsenic Compound Helps Patients with Rare Leukemia Live Longer
June 2, 2007

Adding arsenic trioxide (Trisenox) to standard treatment significantly extends the lives of adults with newly diagnosed acute promyelocytic leukemia (APL), according to a new study. APL is a subtype of acute myeloid leukemia (AML) and accounts for about 1,500 cases in the United States each year. It is most often diagnosed in young and middle-age adults.
Drug for Chronic Myeloid Leukemia Shows 89 Percent Survival After Five Years
June 3, 2006

Results of a clinical trial show that 89% of patients taking imatinib (Gleevec) to treat chronic myeloid leukemia (CML) are alive five years later. This is the longest and largest study of imatinib for newly-diagnosed patients with CML.
Oral Chemotherapy Drug Shows Promise in Treating People Living with AML
June 1, 2003
In leukemia, immature blood cells, called blasts, become stuck in their early stage of development. In the acute phase of the disease, these blasts reproduce rapidly, take over the bone marrow, and crowd out the normal, mature red and white blood cells and platelets that are produced there.
<<Previous | Page 1 of 1 | Next>>